Inebilizumab Shows Sustained Benefits for Myasthenia Gravis

Patients with generalized myasthenia gravis saw consistent improvements in function one year into treatment.

Updated on Oct. 21, 2026 in Alzheimer’s

A glass beaker on a laboratory bench with refracted light, representing scientific precision in clinical treatment. — Long-term data from the phase III MINT trial demonstrates that inebilizumab provides sustained improvements in muscle function for myasthenia gravis patients. AI Illustration. Upload story photo >

Live Poll

Does seeing long-term study data on medication effectiveness increase your confidence in that treatment?

Long-term data from the phase III MINT trial indicates that inebilizumab maintains its efficacy and safety profile in patients with generalized myasthenia gravis. The results show sustained improvements in daily functioning and muscle strength for those who continued treatment in an open-label extension.

Why it matters

For patients living with generalized myasthenia gravis, sustained symptom management is critical for daily quality of life and long-term care stability. This one-year update suggests that the clinical benefits observed during initial treatment phases continue for those managing this autoimmune condition.

In a phase III randomized trial, 190 patients with AChR-antibody and 48 patients with MuSK-antibody showed sustained improvements in MG-ADL and QMG scores over a one-year open-label period. While these results show ongoing clinical stability, researchers continue to track data through a planned three-year extension.

The players

MINT Trial

A clinical research study evaluating the efficacy and safety of inebilizumab in patients with generalized myasthenia gravis.

The details

The MINT trial assessed the efficacy of inebilizumab in patients who had completed an initial randomized controlled period of 52 weeks for the AChR group or 26 weeks for the MuSK group. Patients who initially received a placebo transitioned into active treatment during an open-label extension that can last up to three years. The drug targets specific immune pathways involved in the autoimmune attack on neuromuscular junctions, and current follow-up confirms that these positive clinical effects and the treatment's tolerability remain consistent over time.

December 2025: The FDA approved inebilizumab for generalized myasthenia gravis.
October 20, 2026: Interim one-year open-label follow-up results were presented.

Health Landscape

The MINT trial continues to build the evidence base for targeted immunomodulatory therapies in the treatment of generalized myasthenia gravis. This study represents an evolving shift toward long-term maintenance of function for patients with autoimmune neuromuscular conditions.

Patients currently managing generalized myasthenia gravis may find these one-year results a helpful point of discussion during upcoming consultations with their neurologist. It is important to talk with your physician about how these long-term clinical findings apply to your personal treatment plan.

The takeaway

The one-year follow-up results reinforce the potential for sustained symptom control in patients with generalized myasthenia gravis. If you are currently undergoing treatment, consider discussing the duration and long-term goals of your therapy with your care team during your next visit.